Objective： To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation...Objective： To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Methods： Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time（ACT）, clot rate（CR） and platelet function（PF） by Sonoclot coagulation and platelet function analyzer instrument. Results： For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear（or log linear） relationship between ACT, CR, PF value and drug concentration（P〈0.01）. Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride（P〈0.01）. Under the same ACT values, the puerarin corresponding CR values（CR = e^（-0.0062） ACT＋4.31, P〈2.2 e^（-16）） were always higher than the corresponding values（CR = e-^（0.0028） ACT＋2.79, P-value〈2.2 e^（-16）） of heparin sodium. For high concentrations of puerarin（e.g. 3.8 mg/600 μL） and tirofiban hydrochloride（e.g. 0.8 μg/600 μL）, PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance. Conclusions： Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.展开更多
Background As the most effective approach in treatment of revascularization in coronary perfusion for acute coronary syndromes（ACSs）, percutaneous coronary intervention（PCI） can also increase the risk of detachmen...Background As the most effective approach in treatment of revascularization in coronary perfusion for acute coronary syndromes（ACSs）, percutaneous coronary intervention（PCI） can also increase the risk of detachment of thrombus and embolism of distal microcirculation. Tirofiban hydrochloride is a reversible antagonist of platelet glycoprotein Ⅱb / Ⅲa receptor, which can inhibit platelet aggregation quickly. However,it may also increase the risk of bleeding when in combination with other anti-thrombus drugs. It is important in medication observation for charge nurse when using Ⅱ b / Ⅲ a receptor inhibitor. Methods For 116 elderly patients with ACS who had transradial coronary interventional therapy combined with tirofiban hydrochloride,we conducted medication care, nursing observation of hemorrhage, nursing of puncture of upper limb,postoperative adverse cardiovascular events, observation of myocardial perfusion, blood flow and health education. Results A total of 10 patients had mild bleeding, no serious bleeding, and 2 with major adverse cardiac event（MACE）. Conclusions Tirofiban hydrochloride after PCI can significantly reduce cardiovascular events in acute coronary syndromes, but there is an increased risk of bleeding. It showed that strengthen inspection, closely observe condition and detecting bleeding in time after PCI can significantly reduce postoperative complications for charge nurses.展开更多
目的对盐酸替罗非班治疗冠心病患者的有效性探究。方法随机选择2019年12月—2020年12月于莱州市人民医院心内科就诊的冠心病患者90例作为研究对象,进行前瞻性随机对照研究,分为观察组(盐酸替罗非班+直接PCI,45例)和对照组(直接PCI,45例...目的对盐酸替罗非班治疗冠心病患者的有效性探究。方法随机选择2019年12月—2020年12月于莱州市人民医院心内科就诊的冠心病患者90例作为研究对象,进行前瞻性随机对照研究,分为观察组(盐酸替罗非班+直接PCI,45例)和对照组(直接PCI,45例)。分析比较两组患者经皮冠状动脉支架植入(percutaneous coronary inter vention,PCI)术后即刻血流分级(thrombolysis in myocardial infarction,TIMI),术后6、12 h肌酸激酶同工酶变化,术后7 d左室射血分数,术后1个月内不良心血管事件。结果观察组PCI术后即刻TIMI1、2、3级血流优于对照组,差异有统计学意义(Z=-4.493,P<0.001);观察组心血管不良事件发生率(2.22%)低于对照组(22.22%),差异有统计学意义(χ^(2)=8.389,P=0.004)。结论盐酸替罗非班在治疗冠心病患者治疗中起到有效作用,能降低冠心病患者的不良反应发生率,其安全性较高。展开更多
基金Supported by the 1st-class General Financial Grant from the China Postdoctoral Science Foundation(No.2016M590188)
文摘Objective： To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Methods： Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time（ACT）, clot rate（CR） and platelet function（PF） by Sonoclot coagulation and platelet function analyzer instrument. Results： For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear（or log linear） relationship between ACT, CR, PF value and drug concentration（P〈0.01）. Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride（P〈0.01）. Under the same ACT values, the puerarin corresponding CR values（CR = e^（-0.0062） ACT＋4.31, P〈2.2 e^（-16）） were always higher than the corresponding values（CR = e-^（0.0028） ACT＋2.79, P-value〈2.2 e^（-16）） of heparin sodium. For high concentrations of puerarin（e.g. 3.8 mg/600 μL） and tirofiban hydrochloride（e.g. 0.8 μg/600 μL）, PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance. Conclusions： Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.
文摘Background As the most effective approach in treatment of revascularization in coronary perfusion for acute coronary syndromes（ACSs）, percutaneous coronary intervention（PCI） can also increase the risk of detachment of thrombus and embolism of distal microcirculation. Tirofiban hydrochloride is a reversible antagonist of platelet glycoprotein Ⅱb / Ⅲa receptor, which can inhibit platelet aggregation quickly. However,it may also increase the risk of bleeding when in combination with other anti-thrombus drugs. It is important in medication observation for charge nurse when using Ⅱ b / Ⅲ a receptor inhibitor. Methods For 116 elderly patients with ACS who had transradial coronary interventional therapy combined with tirofiban hydrochloride,we conducted medication care, nursing observation of hemorrhage, nursing of puncture of upper limb,postoperative adverse cardiovascular events, observation of myocardial perfusion, blood flow and health education. Results A total of 10 patients had mild bleeding, no serious bleeding, and 2 with major adverse cardiac event（MACE）. Conclusions Tirofiban hydrochloride after PCI can significantly reduce cardiovascular events in acute coronary syndromes, but there is an increased risk of bleeding. It showed that strengthen inspection, closely observe condition and detecting bleeding in time after PCI can significantly reduce postoperative complications for charge nurses.
文摘目的:观察静脉溶栓后应用银杏叶提取物(Ginkgo biloba extract,EGB)-761联合盐酸替罗非班注射液治疗急性脑梗死的疗效及对血清同型半胱氨酸(homocysteine,Hcy)、血管内皮生长因子(vascular endothelial growth factor,VEGF)水平和活化凝血因子VII/凝血因子VII抗原(activated coagulation factor VII/coagulation factor VII antigen,FVIIa/FVIIAg)比值的影响。方法:选取河南大学第一附属医院2022年1月至12月收治的368例急性脑梗死患者为研究对象,根据患者入院顺序采用奇偶数分组法分为观察组(n=188)和对照组(n=180)。2组均给予静脉溶栓,对照组给予盐酸替罗非班注射液治疗,观察组在对照组基础上联合EGB-761治疗。比较2组Hcy、FVIIa/FVIIAg比值、VEGF、趋化因子CXC配体(chemokine CXC ligand,CXCL-12)、大脑中动脉血流指标的差异,评估2组斑块数量、面积及巴塞尔指数(Barthel index,BI)、弥散加权成像和Alberta卒中项目早期CT评分(diffusion-weighted imaging and early CT in the Alberta Stroke Program Score,DWI-ASPECTS)水平,统计2组疗效。结果:治疗前,2组Hcy、FVIIa/FVIIAg比值、VEGF、CXCL-12比较,差异均无统计学意义(均P>0.05)。与本组治疗前比较,治疗后2组Hcy、CXCL-12水平和FVIIa/FVIIAg比值均下降,且与对照组比较,观察组更低(均P<0.01);2组VEGF均升高,且与对照组比较,观察组更高(均P<0.01)。治疗前,2组斑块数量、面积、大脑中动脉血流指标比较,差异均无统计学意义(均P>0.05)。与本组治疗前比较,治疗后2组斑块数量、面积及大脑中动脉搏动指数(pulsatility index,PI)均下降,且与对照组比较,观察组更低(均P<0.01)。2组大脑中动脉平均血流速度(mean blood flow velocity,Vm)、舒张末期血流速度(enddiastolic blood flow velocity,Vd)均升高,且与对照组比较,观察组更高(均P<0.01)。观察组总有效率为95.21%(179/188),高于对照组的89.44%(161/180),差异有统计学意义(P<0.05)。治疗前,2组BI、DWI-ASPECTS比较,差异均无统计学意义(均P>0.05)。与本组治疗前比较,治疗后2组BI、DWI-ASPECTS均升高,且与对照组比较,观察组更高(均P<0.01)。结论:静脉溶栓后应用EGB-761联合盐酸替罗非班注射液治疗可通过调节患者的血清Hcy和VEGF表达及FVIIa/FVIIAg比值,增加脑血流量,减少颈动脉斑块,从而改善急性脑梗死患者的预后。
文摘目的对盐酸替罗非班治疗冠心病患者的有效性探究。方法随机选择2019年12月—2020年12月于莱州市人民医院心内科就诊的冠心病患者90例作为研究对象,进行前瞻性随机对照研究,分为观察组(盐酸替罗非班+直接PCI,45例)和对照组(直接PCI,45例)。分析比较两组患者经皮冠状动脉支架植入(percutaneous coronary inter vention,PCI)术后即刻血流分级(thrombolysis in myocardial infarction,TIMI),术后6、12 h肌酸激酶同工酶变化,术后7 d左室射血分数,术后1个月内不良心血管事件。结果观察组PCI术后即刻TIMI1、2、3级血流优于对照组,差异有统计学意义(Z=-4.493,P<0.001);观察组心血管不良事件发生率(2.22%)低于对照组(22.22%),差异有统计学意义(χ^(2)=8.389,P=0.004)。结论盐酸替罗非班在治疗冠心病患者治疗中起到有效作用,能降低冠心病患者的不良反应发生率,其安全性较高。
